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ABSTRACT 
Background: Accurate and reliable diagnosis of HIV opportunistic infections plays a central role in effective HIV 
intervention programmes. Pulmonary infections are the leading cause of morbidity and mortality in HIV infected 
individuals. 
Objectives: We set out to determine the prevalence of Pulmonary candidiasis by isolating Candida species from the 
sputum of HIV sero-positive patient’s presenting to hospital with complaint of cough for more than two weeks and 
related the level of CD4 count to Pulmonary candidiasis.  
Methods: Using sterile wire loop, each sputum sample was inoculated into duplicate SDA (Thermo Scientific, UK); one 
tube without antibiotics, another tube supplemented with Chloramphenicol (0.05%) and Cycloheximide (0.5%) 
antibiotics. The patient’s CD4 count was determined using a Cyflow machine (PARTECR, Germany). 
Result: Fifty two (54.2%) female and 44(45.8%) male HIV positive subjects were compared with a control group made up 
of, 52(54.2%) female and 44(45.8%) male HIV negative subjects. Twenty one (21.9%) HIV positive subjects had Candida 
species in their sputum samples compared to 12(12.5%) in the HIV negative subjects. Among HIV positive subjects, 
17(17.7%) had Candida albicans isolated from their sputum, 11(11.5%) of whom had a CD4 count of <200 cells/ul.  
Conclusion: We concluded that, there is a risk of pulmonary candidiasis occurring in HIV infected patients with CD4 
count <200cells/ul and that, Candida species contributes to chronic cough experienced by HIV infected patients. We 
recommend that HIV positive patients who have chronic cough and whose CD4 count is <200cells/ul be placed on 
systemic antifungal medication. 
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RÉSUMÉ  
 
CONTEXTE : Diagnosticprécis et fiable des infections opportunistes joue un rôle central dans l’efficace du 
programme d’intervention de VIH. Les infections pulmonaires sont les causes principales de morbidité et 
mortalité chez les individus infectés par le VIH. 
OBJECTIFS : Nous avons cherché à déterminer la prévalence de Candidose Pulmonaire en isolant les espèces 
de Candida des expectorations des patients VIH séropositifsprésentant a l’hôpital les plaintes de toux 
pendant plus de deux semaines et lie le niveau de numération lymphocytes CD₄alaCandidosePulmonaire.
METHODES : Utilisant boucle de fil stérile, chaque échantillon d’expectoration a été inoculé en double 
exemplaire SDA (Thermo Scientific, UK) ; un tube sans antibiotiques, un autre tube complété d’antibiotiques 
Chloramphénicol (0,05%) et Cycloheximide (0,5%). La numération lymphocytes CD₄ du patient a été 
déterminé en utilisant un Machine CyFlow (PARTECᴿ,Germany). 
RESULTAT : Cinquante – deux (54,2%) sujets féminins et 44(45,8%) sujets masculins VIH positifs ont été 




négatifs. Vingt et – un(21,9%) sujets VIH positifs ont eu des espècesCandida dans leurs échantillons 
d’expectoration comparativement à 12(2,5%) dans les sujets séronégatifs. Parmi les sujets séropositifs, 17 
(17,7%) ont eu Candida albicansisolé de leur expectoration, 11(11,5%) d’entre eux ont eu la numération 
lymphocytes CD₄ de <200 cellules/ul. 
CONCLUSION : Nous avons conclu qu’il ya une risque de Candidose Pulmonaire se produisant chez les 
patients infectés par le VIH de numération lymphocytes CD₄ de <200 cellules/ul et que, Candida species 
contribue à une toux chronique vécué par les patients infectés par le VIH. Nous recommandons que les 
patients séropositifs qui ont une toux chronique et dont la numération lymphocytes est <200 cellules/ulêtre 
place sur l’antifongique systématique médicament. 
Mots – Clés : Candida, La toux, Nigeria, Expectoration. 
INTRODUCTION 
Candida species have been increasingly recognized 
as a source of fungal pneumonia in patients with 
acquired immune deficiency syndrome (1,2). 
Candidiasis is a common endogenous opportunistic 
yeast infection (3). Candidiasis may present as an 
acute, chronic, superficial or disseminated infection 
(2). It is a worldwide infection affecting all age, sex 
and occupational groups. Pulmonary infections are 
the leading causes of morbidity and mortality 
infections in HIV infected individuals (4,5). 
Pulmonary candidiasis is characterized by low 
grade fever, cough with mucous and sometimes 
bloodstained sputum as well as pleural effusion. Of 
the causative agents, the most common is Candida 
albicans (3). While other Candida yeast may 
occasionally cause clinical disease, Candida albicans 
is the organism isolated from most patients (6). 
Candida species are true opportunistic pathogens 
that exploit recent technological advances to gain 
access to blood circulation and deep tissues (7,8). 
Soon after the Acquired Immunodeficiency 
Syndrome (AIDS) was first described in 1981, it 
became clear that opportunistic infections (OIs) 
occurred with remarkable frequency and caused 
substantial morbidity and mortality among patients 
with AIDS (9,10). Many of the OIs in adults are 
usually secondary to activation of “innocent” 
pathogens, which were commensals existing 
passively at a time when host immunity was intact, 
before the acquisition of HIV infection (11). Clinical 
AIDS is a common finding in many HIV health care 
facilities in Nigeria (12,13). 
Among the various OIs, respiratory infections 
account for up to 70% of AIDS defining illnesses 
and their relative importance differs in different 
parts of the world (14,15). Respiratory OIs are a 
common manifestation of HIV/AIDS in Nigeria 
(16). Sixty percent of patients seen in the Jos 
University Teaching Hospital (JUTH) with AIDS 
presented with respiratory tract infections, ranging 
from sinusitis, to upper and lower respiratory tract 
infections (17). 
A diagnosis of Candida pneumonia is difficult to 
establish in immune compromised patients (1). 
Making a diagnosis of candidiasis may often be 
difficult, but the risk factors associated with the 
condition are well known and are commonly found 
in the intensive care units (18). The presence of one 
or more risk factors should therefore heighten 
clinical suspicion (14). Clearly, a thorough 
understanding of the natural history of AIDS 
related OIs and a comprehensive analysis of the 
pace and quality of immune recovery in each 
patient is required for optimal management of this 
condition (15). 
In tropical medical practice, chronic cough, fever 
and weight loss presenting in a clinic, raises a 
suspicion of pulmonary tuberculosis (PTB) until 
ruled out, given the prevalence of PTB in the 
environment. Therefore sputum acid fast bacilli 
(AFB) examinations as well as chest x-ray (CXR) are 
ordered for; the patient is often started on anti-
tuberculosis therapy immediately. In the absence of 
determination of other cause, even when sputum 
returns negative for AFB, treatment is continued 
empirically anyway (17). When the response to the 
anti-tuberculosis treatment is poor or absent, the 
tendency is more likely to be to doubt the patients 
drug compliance, genuineness of the drugs used or 
suspect drug resistant PTB. Cases like this are 
common in tropical medical practice and 
pulmonary mycosis is rarely thought of as a likely 
cause of these symptoms (18,19). 
The HIV/AIDS patients presenting with 
respiratory tract symptoms like cough, 
breathlessness and chest pain will need detailed 
investigations including sputum microscopy (Gram 
and AFB staining), culture and chest X-ray (CXR).  
To date, few, if any, rigorous studies on the causes 
of chronic cough in African, treatment-naive, HIV 
infected patients have been performed (20,21). As 
regards the diagnosis of pneumonia, there is little 
information about the role of Candida species 
isolated from respiratory samples, and criteria for 
the diagnosis of Candida species pneumonia are 
still to be defined (22,23). Such analyses are helpful 
for determining the preventive medications and 
treatment needed for HIV- infected persons (24). 
The aim of this study was to determine the 
prevalence of Candida species in the sputum of 




of Differentiation (CD4) cell count to presence or 
otherwise of Candida species in the subject. 
MATERIALS  
Patients from 18 years old who presented to JUTH 
ARV treatment clinic and who have been coughing 
for at least two weeks were referred to a TB 
Reference Laboratory for sputum AFB microscopy, 
culture and sensitivity. These were the candidates 
that were approached to be recruited and asked for 
consent to be included in this study. 
At the TB reference laboratory, patients included 
were selected statistically, using simple random 
sampling method (25,26). Patients on anti-
tuberculosis or anti mycoses treatment, were 
excluded as well as any patient who had ever 
smoked or is currently smoking cigarette, any who 
presents with pedal edema or history of heart 
failure. Written informed consent was obtained and 
it was made clear to each patient that he/she was 
free to opt out from the study at any time.  
 Sputum samples were obtained from 96 HIV sero 
positive patients (case) who have been coughing for 
at least two weeks. A marching patient based on 
sex and age group presenting on the same day, who 
is HIV negative from other clinics presenting to the 
TB reference laboratory, at the same period are 
selected as a control. Patients who later failed to 
produce up to three fresh sputum samples as 
instructed were excluded. One hundred and five 
patients who fulfilled the inclusion criteria were 
recruited for the study; the extra 9 patients were 
added to make room for attrition during the study.  
Baseline blood samples were taken for CD4 
lymphocyte count. Ethical clearance for the study 
was obtained from the Jos University Teaching 
Hospital’s Ethics Committee.  
Two hundred and eighty eight (96x3) sputum 
samples and 96 baseline blood samples for CD4 
count were obtained from these patients. Similarly 
288 sputum samples were collected from HIV 
negative control patients who had chronic cough, 
fever and weight loss.  
LABORATORY PROCEDURE 
The patients’ confidence was boasted through 
explanation of the reasons for the collection of the 
sputum. Three separate sputum specimens were 
collected from each patient (spot, morning, spot) 
(27,28). A gram stained smear was immediately 
prepared from each freshly produced sputum 
sample submitted to assess the quality of the 
sputum before it was accepted for the study. Then 
using a sterile wire loop, the sputum was 
inoculated into duplicate Sabouraud Dextrose agar 
tubes (SDA, Thermo scientific, UK); a tube without 
antibiotics, a tube supplemented with 
Chloramphenicol (0.05%) and Cycloheximide 
(0.5%) antibiotics. Yeast growth to be analysed is 
collected and emulsified in sterile water to 
McFarland 0.5 equivalent. The analytic profile 
index (API) 20C Aux (Biomerieux, France) was then 
used to identify the yeast encountered (29). This 
was guided by the accompanying manufacturers 
database (V4.0) – with the API looked up and the 
numerical profile determined from the list of 
provided profiles. 
Using lavender coloured EDTA vacutainer, about 
5mls of blood was withdrawn using the cubital 
fossa vein of each of the selected patient. The 
patient’s CD4 count was determined using a Cyflow 
machine (PARTECR, Germany), observing peaks 
generated and the count read after the run from the 
Cyflow monitor screen.  Data was analysed using 
SPSS statistical package. Proportions were 
compared using X2 test, differences at the 5% level 
being regarded as significant (25,26). 
RESULTS 
Fifty two (54.2%) females and 44 (45.8%) males HIV 
positive patients were compared with a control 
group made up of, 52(54.2%) females and 44(45.8%) 
males HIV negative patients. Among the cases 49 
(50.7%) females and 34 (35.6%) males were below 
the age of 45 years. Above the age of 45 years, 3 
(3.1%) females and 10 (10.4%) males presented. 
Cases between the ages of 30-39 years formed the 
largest age group presenting with 25 (26.0%) 
females and 20 (20.5%) males. 
Of the cases studied, 95 (99.0%) presented with 
cough compared to 93 (96.9%) in the control group, 
75 (78.1%) presented with fever compared to 73 
(75.0%) in the control group, 6 (6.3%) with Loss of 
weight compared to 46 (47.9%) in the control group, 
4 (4.1%) with Bloody sputum compared to 20 
(20.8%) in the control group and 3 (3.1%) with 
Night sweats compared to 41 (42.7%) in the control 
group.  
Twenty one (21.9%) HIV positive patient’s sputum 
samples had Candida species compared to 12 
(12.5%) samples in the control group. Seventeen 
(17.8%) patient’s sputum samples out of the 96 HIV 
positive patient’s samples had Candida albicans 
compared to 10 (10.4%) in the control group. All the 
17 HIV positive patients who had Candida albicans 
isolated, from their sputum presented with cough, 
69.2% presented with fever and only one patient 






Nine (9.4%) of the HIV positive patients who had 
Candida albicans isolated from their sputum were 
between the ages of 30-39 years, all were females. 
At P<0.05 these results are statistically significant. 
The age group of 30-39 contributed 9 (9.4%) out of 
45 (46.9%) of patients from whom Candida albicans 
was isolated. This was followed by 4 (4.1%) out of 




TABLE 1: Distribution of Candida albicans isolates 
within the age grouping of HIV positive patients. 
 With Candida Without 
Candida 
Age group Total (%) Total (%) 
15-19 0 (0.0) 0 (0.0) 
20-24 3 (3.1) 10 (10.4) 
25-29 3 (3.1) 12 (12.5) 
30-34 4 (4.2) 13 (13.5) 
35-39 5 (5.2) 21 (21.8) 
40-44 0 (0.0) 11 (11.4) 
45-49 2 (2.1) 7 (7.3) 
50+ 0 (0.0) 5 (5.2) 
Total 17 (17.7) 79 (82.3) 
 
Among the 17(17.7%) HIV positive patients who 
had Candida albicans isolated from them, 11 (11.5%) 
had a CD4 count < 200 cells/ul (8 females, 3 males). 
At P<0.05 these results are statistically significant 





















































Symptoms in presenting patients
FIGURE 1: Presenting symptoms of HIV positive 








TABLE 2: Distribution of CD4 count by Candida albicans isolated among HIV positive patients 
                                                                                      Candida albicans isolates from 
CD4 
count(Cell/ul) 
Males Females Total (%) 
<200 3 8 11 (64.7) 
200-500 4 2 6 (35.3) 
Total 7 10 17 (100) 
X2 = 6.9  d.f. = 1  P< 0.05 
DISCUSSION 
The study set out to determine the prevalence 
of Pulmonary candidiasis by isolating Candida 
species from the sputum of HIV sero-positive 
patient’s presenting to hospital with 
complaints of cough for more than two weeks 
and relate the level of CD4 count to Pulmonary 
candidiasis. There were more female HIV 
positive patients reporting to clinic than were 
male patients. The most common presenting 
symptom among Pulmonary Candidiasis 
patients was cough, closely followed by fever 
and loss of weight. 
The main finding in this study was that HIV 
positive patients in Jos had Candida species in 
their sputum, compared to the HIV negative 
control group. This figure varies from findings 
of other parts of the world, where similar 
studies were carried out. A recognized 
difficulty in studies of this type is the method 
of specimen collection and the sterility of the 
sputum container used (4,7).  In our study the 
patients were provided with sterile bottles and 
only the patients whose three sputum sample 
pairs yielded Candida species were accepted as 
positive for Candida species. 
Our finding is much lower than the 35.5% 
Candida species isolated by Nwabuisi and 
Ologe in Ilorin, Nigeria (30). Castro and 
Martinez in 2008 detected 47.5% candidiasis in 
Brazil, and 60%  was reported in the USA 
(2,14). The finding is however higher than that 
found in Taiwan, and India (31,32).  
Fungi isolated from sputum may represent 
either pathogens or saprophytes (32). The 
prevalence and prognosis of pulmonary fungal 
infection has been difficult to evaluate since 
diagnoses was seldom confirmed (31). 
 
This study agrees with established finding of other 
studies that Candida albicans is the most commonly 
isolated strain of Candida, both as a colonizer in the 
general population and as a pathogen in patients 
infected with HIV (3,4,32). 
In this study the median CD4 count among HIV 
positive patients was lower than found in Zaire (15). 
Many (64.7% ) of our patients who had CD4 count of 
<200cell/ul, had chronic cough and their sputum 
yielded Candida albicans (12,15). This finding in our 
study suggests that the severity of HIV infection is 
directly proportional to the degree of immune 
deficiency as indicated by the CD4 count of the 
patient (8,11,14). 
CONCLUSION  
We concluded that a high number of HIV infected 
patients had Candida species isolated from their 
sputum and had CD4 count <200cells/ul. This 
suggests that, Candida species contributes to chronic 
cough experienced by HIV infected patients and 
that, the most predominant Candida species isolated 
was Candida albicans.   
 
LIMITATIONS  
The limitation of the study was that only HIV 
positive patients who presented to the clinic were 
captured in the study, other HIV positive patients 
who were too sick were admitted directly for in-
patient care from the emergency care unit. 
RECOMMENDATIONS 
We recommend that HIV positive patients who have 
chronic cough and whose CD4 count is <200cells/ul 
be commenced on prophylactic systemic antifungal 
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